News from Watson Pharma

Watson to sell authorized generic of Pravastatin
Watson Pharma announced that under a distribution agreement with Bristol-Myers Squibb (BMS) the Company has initiated shipments of Pravastatin sodium tablets in the 10, 20 and 40 mg. strengths.
Pravastatin sodium distributed by Watson is the authorized generic version of BMS 's Pravachol(R) product and is cholesterol lowering agent.
Watson is also marketing an authorized generic form of Alendronate in agreement with Merck.

Watson filed Para IV on Fentanyl buccal tablet
Cephalon announced its receipt of a Para IV Certification Notice Letter relating to an ANDA submitted to the USFDA by Watson, requesting approval to market and sell a generic version of Fentora (R) (Fentanyl buccal tablet).
In its Notice Letter, Watson alleges that the US6200604 and US 6974590 covering Fentora are invalid, unenforceable and/or will not be infringed by Watson's manufacture, use or sale of the product described in its ANDA.
Cephlon has 45 days time to bring infrigement action against Watson